Brilinta

Discussion in 'AstraZeneca' started by Anonymous, Apr 9, 2012 at 7:25 PM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    A direct quote by the authors of the STEMI substudy from PLATO

    "Although outcomes in the STE-ACS subgroup were generally consistent with those of the overall trial, nominal statistical significance was not reached for all end points and varied according to the definition used."

    If you look at their FOREST Plot, all end points do not reach significance. All definitions were defined by AZ invesigators. The forest plot in Figure 3 is from their study from Circulation, published on November 8th, 2010. There were over 7500 STEMI patients in the PLATO study.

    If you look at Figure 2 (Kalpan Meier Curves)

    Figure 2.
    Time-related Kaplan–Meier estimates of the time to first occurrence of (A) the primary end point (incidence of MI, stroke, or vascular death; HR, 0.87; 95% CI, 0.75 to 1.01; P=0.07) and each of its components.

    Again. please note the P-value of 0.07 = NOT SIGNIFCANT compared to clopidogrel.

    Now I bet the idiot from AZ who calls me a troll will no doubt reply with some other BS. I just like quoting your data and showing how much you really know.

    HAHAHAHAHAHAHAHAHA!
     

  2. Anonymous

    Anonymous Guest

    You are such a DS or Lilly Troll. Effient blows: See below: This is YOUR STEMI data. Effient one that's no better.

    "Discrepancy in these mortality trends dependent on the underlying acute coronary syndrome type adds more confusion to the adequate assessment of TRITON's results and may restrict prasugrel use even further," he concludes.

    Commenting on this issue for heartwire, Serebruany explained that the mortality data from TRITON was particularly important, given the controversy that has surrounded the MI end point. "As the definition of MI used in this trial has been queried, the only hard outcome data we have is mortality, and the fact that this is going the wrong way in the population that makes up three-quarters of the patients treated is alarming to me," he said.

    Serebruany also highlights other mortality statistics not included in the original TRITON paper but included in the documentation made available by the FDA. He writes: "Although cardiovascular deaths trended slightly in favor of prasugrel (133 vs 150), an excess in bleeding fatalities (21 vs five), and four additional cancer-related deaths after prasugrel diluted the mortality benefit almost completely. Moreover, final FDA notes revealed more deaths with unidentified causes after prasugrel (five vs two) in patients lost to follow-up without achieving primary end points but affecting all-cause mortality."

    Hahahahaha. . .
     
  3. Anonymous

    Anonymous Guest

  4. Anonymous

    Anonymous Guest

    4/25/2012 @ 3:17PM
    The Medicines Company Collaborates with AstraZeneca To Sell Brilinta (ticagrelor)

    The Medicines Company will collaborate with AstraZeneca to help sell Brilinta (ticagrelor), AstraZeneca’s struggling oral antiplatelet drug. The collaboration is the first stage of ”a global collaboration for acute ischemic heart disease compound” announced by the two companies today.

    AstraZeneca will pay $15 million per year for The Medicines Company’s Brilinta-related sales activities, scheduled to begin in May. The two companies also plan to collaborate on two other drugs from The Medicines Company, Angiomax (bivalirudin), the direct thrombin inhibitor, and cangrelor, an acute intravenous antiplatelet agent. Details of these collaborations have not yet been established.

    Like many other large pharmaceutical companies, AstraZeneca has been seeking new sources of revenue after the expiration of patents for many of its key drugs. Initial hopes that Brilinta would provide a much-needed boost to the company have so far not been realized. The Medicines Company has also sought to find a successor to Angiomax, which has been the company’s mainstay.
     
  5. Anonymous

    Anonymous Guest

    Struggling? Whaddya mean struggling? We have a premium product. We even raised the price at launch!
     
  6. Anonymous

    Anonymous Guest

    Really? Are you serious? If you want the job take the job. Why would you ask someone on Cafe Pharma to
    make that decision for you? I think they are making a mistake asking someone so immature to work for the company. Grow up.
     
  7. Anonymous

    Anonymous Guest

    Subgroup dumbfuck... trial was not powered for subgroup analysis.... do you think the FDA are idiots ? They granted us an indication stating superiority for the Combinded endpoint... driven by less CV death MI and no difference in stroke. The study also showed a reduction in all cause mortality superior to Plavix with a significant p-value but we don't have an indication because of how the trial was designed...take statistics class and try reading the PI
     
  8. Anonymous

    Anonymous Guest

    Wow, I know. What do you do with people like the PP? Must be the Effient rep freaking out. I tried to explain to him/her earlier with no luck. You are precisely right. You cannot take a subgroup analysis and make a claim of significance or a meaningful p-value. Sub groups only can be used to show trends for adverse events, population or demographic differences. Then those differences can be powered up and studied. STEMI is a tough population and in Europe, many pts sit for longer than 2 hours. This was a European study. At a certain point in time, nothing (no product) is going to make any difference in outcomes that was proven by the OAT Trial. Also, a European trial.
     
  9. Anonymous

    Anonymous Guest

    anyone seen the first quarter sales for Brilinta? any improvement on the 'zero' from the last quarter 2011?!
     
  10. Anonymous

    Anonymous Guest


    Non significant
     
  11. Anonymous

    Anonymous Guest

    The U.S. is going to be slow to ramp up. They always want to wait a good year after a drug comes out before even trying it anymore. Just saying. No drug in the last year that I know of has had a successful "blockbuster-style" launch. Plus, AZ made a huge mistake puting the statin reps as their frontline.
     
  12. Anonymous

    Anonymous Guest


    Yeah, but if you listen to some here they'll make claims that Brilinta is going to be the IC drug of choice over generic Plavix or Effient. There are no indications of that yet. A drug does need SOME momentum to get off the ground and sales are not moving as well as expected.
     
  13. Anonymous

    Anonymous Guest

    So, is it horrible trying to launch this in our no access environment. I am sick of all the overlays and wonder what will happen once Medco reps have this drug too. Thoughts? Is this going to be good or are only the CVAS reps going to win out because of our targeting?
     
  14. Anonymous

    Anonymous Guest

    this co-promote is a last and desperate attempt to resurrect a dead product. Good luck AZ, six months from now when sales are still meager at best, what will you do next?
     
  15. Anonymous

    Anonymous Guest

    Effient rep go back to your board.
     
  16. Anonymous

    Anonymous Guest


    I think the answer will be found when the " collaboration " books come out... if the AZ contact with the new company is a CVAS rep...then we know what AZ's plan is... if it is hospital rep then we also know. Rumor has it that leadership believes hospital reps are not as good sales people... Hospital people don't get your feelings hurt, some are good but most do not have skills to sell a drug like brilinta such as taking 3 months to get a drug in pixus is ridiculous.

    Or if it is the Hospital person that is the contact,,, it means that leadership thinks hospital reps with a little help/training on the ACS departments in the hospital can increase Brilinta sales. And that leadership has finally realized that designing territories that only have 30-40 interventional cardiologists with 3-4 reps calling on them creates a situation of in-fighting and no accountability.
     
  17. Anonymous

    Anonymous Guest

    Well, I was told the hospital people only have business calling on pharmacy because their skillset is so low for this drug. That came from the top.
     
  18. Anonymous

    Anonymous Guest

    Yes, the infighting and blame continues on at AZ. An inability to work together and collaborate. This is what a sick culture has wrought. What a pitiful situation.
     
  19. Anonymous

    Anonymous Guest

    Well that's what happens when everyone is afraid of losing their jobs. It is everywhere not just at AZ. These jobs are high paid but horribly stressful.
     
  20. Anonymous

    Anonymous Guest

    What does that mean?

    What is a drug skill set?

    Its a new customer for AZ.

    There is little knowledge in the company, even less inside HQ, where there isn't even any commercial acumen. Remember this is the leadership team that awarded Vimovo for a great launch.

    The current Brilinta CBL fcked up Symbicort, and the person over the lot led through the decline of Seroquel, Symbicort and Vimovo. (LS) They are totally convinced they are right, despite all evidence to the contrary.

    The lack of HQ knowledege and lack of respect for the sales function led to a shitty strategy. The brand team have no clue about the customer, they don't even truly understand the patient flow or billing flow. And MT has been so busy fcking the sales force he has no cred left in AZ.

    Their performance is an inevitability.

    On top of that the lawyers and the brand team ran 'prevent' on the sales knowledge. They narrowed the clinical knowledge down so much, and even prevented information about the hospital treatement regimens from getting to the field. They are so frightened that an off label conversation will come up, that they made it more likely to come up by restricting the knowledge.

    AZ has been sunk by its own 'intellect'. They never believed in the sales force, despite the salex force being the strongest skill set at AZ. AZ sales was an implementation machine until they fcked with it.

    All that's left in AZ is ass kissers and lawyers. And lawyers who kiss ass.